Ann: Dimerix Receives PIP Approval from the UK MHRA, page-46

Hi Ed,

Are you Mr Meurs? He has supported DXB remarkably since I have been invested. Obviously you have a very large position to state those words.

My thinking is that the next readout will hold the key for DMX-200 being successful to Accelerated Market Approval, and as per recent ANNs, the eGFR slope, well that’s on a continuum over time, and the trial will continue regardless if the PCR remains within that statistical range which is predictive of eGFR slope & improvement in renal function.

The recent CR will ensure that DXB can achieve that goal and therefore be worth far more for any offers forthcoming.

So far so good, and as Nina had stated, that first positive interim analysis was vitally important.

Even IF there is a while to wait it’s nothing on 6-7 years, or longer for some. No need for any Apologies there Ed! Everyone will do their thing. But they aren’t bent over a barrel now, as far as funding the Ph3 trial.

Great to see your support!

Take Care Folks!